Equities analysts forecast that Qiagen N.V. (NASDAQ:QGEN) will announce earnings of $0.32 per share for the current quarter, Zacks reports. Two analysts have provided estimates for Qiagen N.V.’s earnings. The highest EPS estimate is $0.33 and the lowest is $0.31. Qiagen N.V. posted earnings of $0.30 per share in the same quarter last year, which suggests a positive year-over-year growth rate of 6.7%. The company is scheduled to report its next earnings report on Wednesday, November 1st.

According to Zacks, analysts expect that Qiagen N.V. will report full-year earnings of $1.25 per share for the current fiscal year, with EPS estimates ranging from $1.24 to $1.27. For the next financial year, analysts forecast that the company will post earnings of $1.41 per share, with EPS estimates ranging from $1.37 to $1.48. Zacks’ EPS averages are an average based on a survey of research firms that that provide coverage for Qiagen N.V..

Qiagen N.V. (NASDAQ:QGEN) last announced its quarterly earnings results on Thursday, July 27th. The company reported $0.30 EPS for the quarter, beating the Zacks’ consensus estimate of $0.28 by $0.02. The business had revenue of $349 million during the quarter, compared to analyst estimates of $353.09 million. Qiagen N.V. had a net margin of 5.44% and a return on equity of 11.04%. Qiagen N.V.’s quarterly revenue was up 4.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.24 EPS.

QGEN has been the subject of a number of research reports. TheStreet upgraded Qiagen N.V. from a “c” rating to a “b” rating in a report on Monday, June 5th. Barclays PLC reiterated a “buy” rating and issued a $33.00 price objective on shares of Qiagen N.V. in a report on Monday, May 15th. Commerzbank Ag reiterated a “buy” rating on shares of Qiagen N.V. in a report on Monday, May 15th. BidaskClub downgraded Qiagen N.V. from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 10th. Finally, Deutsche Bank AG reiterated a “buy” rating on shares of Qiagen N.V. in a report on Monday, July 24th. Nine investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $33.17.

Shares of Qiagen N.V. (QGEN) traded up 0.47% during mid-day trading on Friday, reaching $32.32. 1,714,644 shares of the company’s stock were exchanged. The stock has a 50-day moving average of $32.58 and a 200 day moving average of $31.43. Qiagen N.V. has a one year low of $24.86 and a one year high of $35.26. The firm has a market capitalization of $7.38 billion, a P/E ratio of 98.84 and a beta of 1.14.

Institutional investors have recently modified their holdings of the stock. Dimensional Fund Advisors LP increased its position in shares of Qiagen N.V. by 58.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 72,909 shares of the company’s stock valued at $2,043,000 after buying an additional 26,838 shares during the last quarter. First Mercantile Trust Co. increased its position in shares of Qiagen N.V. by 27.3% in the first quarter. First Mercantile Trust Co. now owns 14,593 shares of the company’s stock valued at $422,000 after buying an additional 3,126 shares during the last quarter. Wetherby Asset Management Inc. increased its position in shares of Qiagen N.V. by 1.8% in the first quarter. Wetherby Asset Management Inc. now owns 9,273 shares of the company’s stock valued at $269,000 after buying an additional 163 shares during the last quarter. Canada Pension Plan Investment Board increased its position in shares of Qiagen N.V. by 1,128.0% in the first quarter. Canada Pension Plan Investment Board now owns 481,483 shares of the company’s stock valued at $14,012,000 after buying an additional 442,274 shares during the last quarter. Finally, First Trust Advisors LP increased its position in shares of Qiagen N.V. by 8.1% in the first quarter. First Trust Advisors LP now owns 1,117,349 shares of the company’s stock valued at $32,370,000 after buying an additional 83,856 shares during the last quarter. Hedge funds and other institutional investors own 63.01% of the company’s stock.

WARNING: “$0.32 EPS Expected for Qiagen N.V. (QGEN) This Quarter” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.thecerbatgem.com/2017/09/01/0-32-eps-expected-for-qiagen-n-v-qgen-this-quarter.html.

About Qiagen N.V.

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Get a free copy of the Zacks research report on Qiagen N.V. (QGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Qiagen N.V. (NASDAQ:QGEN)

Receive News & Stock Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related stocks with our FREE daily email newsletter.